The Clinical and Biologic Importance of Neovascularization and Angiogenic Signaling Pathways in Chronic Lymphocytic Leukemia

Seminars in Oncology

Volumn 33, Issue 2, 2006, Pages 174-185

  Shanafelt, Tait D ^a   Kay, Neil E ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; APOPTOSIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; BIOLOGICAL MARKER; CLADRIBINE; CYTOKINE; CYTOKINE ANTIBODY; EPIGALLOCATECHIN GALLATE; FLUDARABINE; LENALIDOMIDE; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; SMALL INTERFERING RNA; THALIDOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; B LYMPHOCYTE; BONE MARROW; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CELL INTERACTION; CELL MATURATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG EFFICACY; FEVER; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HUMAN; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LYMPH NODE; LYMPHADENOPATHY; LYMPHOCYTOSIS; METASTASIS; MICROENVIRONMENT; MULTIPLE MYELOMA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SECRETION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SOLID TUMOR; UPREGULATION;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; BONE MARROW; CLINICAL TRIALS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPH NODES; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 33645997037     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.01.008     Document Type: Article

References (140)

1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29 (2002) 15-18
2. Folkman J. Tumor angiogenesis. Therapeutic implications. N Engl J Med 285 (1971) 1182-1186
3. Gimbrone Jr. M.A., Leapman S.B., Cotran R.S., et al. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 136 (1972) 261-276
4. Folkman J., and Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 22 (1991) 339-347
5. Sugimachi K., Tanaka S., Terashi T., et al. The mechanisms of angiogenesis in hepatocellular carcinoma. Angiogenic switch during tumor progression. Surgery 131 (2002) S135-S141
6. Tosetti F., Benelli R., and Albini A. The angiogenic switch in solid tumors. Clinical implications. Tumori 1 suppl (2002) S9-S11
7. Volpert O.V., and Alani R.M. Wiring the angiogenic switch. Ras, Myc, and thrombospondin-1. Cancer Cell 3 (2003) 199-200
8. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
9. Mercurio A.M., Bachelder R.E., Bates R.C., et al. Autocrine signaling in carcinoma. VEGF and the alpha6beta4 integrin. Semin Cancer Biol 14 (2004) 115-122
10. Brown J.M. The hypoxic cell. A target for selective cancer therapy-Eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 59 (1999) 5863-5870
11. Brizel D.M., Scully S.P., Harrelson J.M., et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56 (1996) 941-943
12. Hockel M., Schlenger K., Aral B., et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56 (1996) 4509-4515
13. Dvorak H.F., Nagy J.A., Feng D., et al. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 237 (1999) 97-132
14. Robinson C.J., and Stringer S.E. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 114 (2001) 853-865
15. Lee S., Jilani S.M., Nikolova G.V., et al. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169 (2005) 681-691
16. Clauss M., Weich H., Breier G., et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 271 (1996) 17629-17634
17. Gerwins P., Skoldenberg E., and Claesson-Welsh L. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit Rev Oncol Hematol 34 (2000) 185-194
18. Meyer M., Clauss M., Lepple-Wienhues A., et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 18 (1999) 363-374
19. Wise L.M., Veikkola T., Mercer A.A., et al. Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1. Proc Natl Acad Sci U S A 96 (1999) 3071-3076
20. Gerber H.P., McMurtrey A., Kowalski J., et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273 (1998) 30336-30343
21. Carmeliet P., Lampugnani M.G., Moons L., et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98 (1999) 147-157
22. Karkkainen M.J., and Petrova T.V. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 19 (2000) 5598-5605
23. Ross J.S., Schenkein D.P., Pietrusko R., et al. Targeted therapies for cancer 2004. Am J Clin Pathol 122 (2004) 598-609
24. Folkman J. Endogenous angiogenesis inhibitors. Apmis 112 (2004) 496-507
25. Schiffelers R.M., van Rooy I., and Storm G. siRNA-mediated inhibition of angiogenesis. Expert Opin Biol Ther 5 (2005) 359-368
26. Veronese M.L., and O'Dwyer P.J. Monoclonal antibodies in the treatment of colorectal cancer. Eur J Cancer 40 (2004) 1292-1301
27. Sandler A.B., Gray R., Brahmer J., et al. Randomized phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC). An Eastern Cooperative Oncology (ECOG) Trial -E4599. Proc Am Soc Clin Oncol LBA4 (2005) abstr
28. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
29. Carmeliet P., Ferreira V., Breier G., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380 (1996) 435-439
30. Ferrara N., Carver-Moore K., Chen H., et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380 (1996) 439-442
31. Shalaby F., Rossant J., Yamaguchi T.P., et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376 (1995) 62-66
32. Gerber H.P., Malik A.K., Solar G.P., et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417 (2002) 954-958
33. Ziegler B.L., Valtieri M., Porada G.A., et al. KDR receptor. A key marker defining hematopoietic stem cells. Science 285 (1999) 1553-1558
34. Vacca A., Ribatti D., Roncali L., et al. Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. Leuk Lymphoma 20 (1995) 27-38
35. Hussong J.W., Rodgers G.M., and Shami P.J. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 95 (2000) 309-313
36. Pruneri G., Bertolini F., Soligo D., et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer 81 (1999) 1398-1401
37. Lundberg L.G., Lerner R., Sundelin P., et al. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol 157 (2000) 15-19
38. Mesa R.A., Hanson C.A., Rajkumar S.V., et al. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 96 (2000) 3374-3380
39. Perez-Atayde A.R., Sallan S.E., Tedrow U., et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 150 (1997) 815-821
40. Aguayo A., Kantarjian H., Manshouri T., et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 96 (2000) 2240-2245
41. Ridell B., and Norrby K. Intratumoral microvascular density in malignant lymphomas of B-cell origin. Apmis 109 (2001) 66-72
42. Skobe M., Rockwell P., Goldstein N., et al. Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 3 (1997) 1222-1227
43. Prewett M., Huber J., Li Y., et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59 (1999) 5209-5218
44. Folkman J. Angiogenesis and angiogenesis inhibition. An overview. Exs 79 (1997) 1-8
45. Fiedler W., Graeven U., Ergun S., et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 89 (1997) 1870-1875
46. Dias S., Hattori K., Zhu Z., et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 106 (2000) 511-521
47. Masood R., Cai J., Zheng T., et al. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc Natl Acad Sci U S A 94 (1997) 979-984
48. Masood R., Cai J., Zheng T., et al. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 98 (2001) 1904-1913
49. Santos S.C., and Dias S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood 103 (2004) 3883-3889
50. Bellamy W.T., Richter L., Frutiger Y., et al. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 59 (1999) 728-733
51. Wang L., Chen L., Benincosa J., et al. VEGF-induced phosphorylation of Bcl-2 influences B lineage leukemic cell response to apoptotic stimuli. Leukemia 19 (2005) 344-353
52. Vacca A., Ribatti D., Roncali L., et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 87 (1994) 503-508
53. Kumar S., Fonseca R., Dispenzieri A., et al. Bone marrow angiogenesis in multiple myeloma. Effect of therapy. Br J Haematol 119 (2002) 665-671
54. Rajkumar S.V., Leong T., Roche P.C., et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 6 (2000) 3111-3116
55. Vacca A., Ribatti D., Ruco L., et al. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer 79 (1999) 965-970
56. Bertolini F., Paolucci M., Peccatori F., et al. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol 106 (1999) 504-509
57. Salven P., Teerenhovi L., and Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 90 (1997) 3167-3172
58. Salven P., Teerenhovi L., and Joensuu H. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood 94 (1999) 3334-3339
59. Salven P., Orpana A., Teerenhovi L., et al. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma. A single-institution study of 200 patients. Blood 96 (2000) 3712-3718
60. Aguayo A., Estey E., Kantarjian H., et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 94 (1999) 3717-3721
61. Kumar S., Witzig T.E., Dispenzieri A., et al. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia 18 (2004) 624-627
62. Kvasnicka H.M., Thiele J., Staib P., et al. Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy. Blood 103 (2004) 3549-3551
63. Bertolini F., Mingrone W., Alietti A., et al. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. Ann Oncol 12 (2001) 987-990
64. Legros L., Bourcier C., Jacquel A., et al. Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia. Blood 104 (2004) 495-501
65. Singhal S., Mehta J., Desikan R., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341 (1999) 1565-1571
66. Rajkumar S.V., Fonseca R., Witzig T.E., et al. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia 13 (1999) 469-472
67. Kini A.R., Kay N.E., and Peterson L.C. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia 14 (2000) 1414-1418
68. Molica S., Vacca A., Ribatti D., et al. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood 100 (2002) 3344-3351
69. Wolowiec D., Wozniak Z., Potoczek S., et al. Bone marrow angiogenesis and proliferation in B-cell chronic lymphocytic leukemia. Anal Quant Cytol Histol 26 (2004) 263-270
70. Chen H., Treweeke A.T., West D.C., et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood 96 (2000) 3181-3187
71. Molica S., Vacca A., Crivellato E., et al. Tryptase-positive mast cells predict clinical outcome of patients with early B-cell chronic lymphocytic leukemia. Eur J Haematol 71 (2003) 137-139
72. Ribatti D., Molica S., Vacca A., et al. Tryptase-positive mast cells correlate positively with bone marrow angiogenesis in B-cell chronic lymphocytic leukemia. Leukemia 17 (2003) 1428-1430
73. Fuhrmann-Benzakein E., Ma M.N., Rubbia-Brandt L., et al. Elevated levels of angiogenic cytokines in the plasma of cancer patients. Int J Cancer 85 (2000) 40-45
74. Banks R.E., Forbes M.A., Kinsey S.E., et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets. significance for VEGF measurements and cancer biology. Br J Cancer 77 (1998) 956-964
75. Gora-Tybor J., Blonski J.Z., and Robak T. Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia. Mediators Inflamm 12 (2003) 167-171
76. Duensing S., and Atzpodien J. Increased intracellular and plasma levels of basic fibroblast growth factor in B-cell chronic lymphocytic leukemia. Blood 85 (1995) 1978-1980
77. Molica S., Vitelli G., Levato D., et al. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. Br J Haematol 107 (1999) 605-610
78. Aguayo A., O'Brien S., Keating M., et al. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood 96 (2000) 768-770
79. Menzel T., Rahman Z., Calleja E., et al. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood 87 (1996) 1056-1063
80. Molica S., Vitelli G., Levato D., et al. Serum angiogenin is not elevated in patients with early B-cell chronic lymphocytic leukemia but is prognostic factor for disease progression. Eur J Haematol 73 (2004) 36-42
81. Fink S.R., Paternoster S.F., Smoley S.A., et al. Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic lymphocytic leukemia. Leuk Res 29 (2005) 253-262
82. Kay N.E., Bone N.D., Tschumper R.C., et al. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia 16 (2002) 911-919
83. Hevehan D.L., Papoutsakis E.T., and Miller W.M. Physiologically significant effects of pH and oxygen tension on granulopoiesis. Exp Hematol 28 (2000) 267-275
84. Aguayo A., Manshouri T., O'Brien S., et al. Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL). Leuk Res 25 (2001) 279-285
85. Bairey O., Boycov O., Kaganovsky E., et al. All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells. Leuk Res 28 (2004) 243-248
86. Ferrajoli A., Manshouri T., Estrov Z., et al. High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res 7 (2001) 795-799
87. Lee Y.K., Bone N.D., Strege A.K., et al. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood 104 (2004) 788-794
88. Lee Y.K., Shanafelt T.D., Bone N.D., et al. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3. Implication for apoptosis resistance. Leukemia 19 (2005) 513-523
89. Wang L., Coad J.E., Fortney J.M., et al. VEGF-induced survival of chronic lymphocytic leukemia is independent of Bcl-2 phosphorylation. Leukemia 19 (2005) 1486-1487
90. Funamoto M., Fujio Y., Kunisada K., et al. Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes. J Biol Chem 275 (2000) 10561-10566
91. Niu G., Wright K.L., Huang M., et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21 (2002) 2000-2008
92. Bartoli M., Gu X., Tsai N.T., et al. Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells. J Biol Chem 275 (2000) 33189-33192
93. Frank D.A., Mahajan S., and Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest 100 (1997) 3140-3148
94. Liu H., Ma Y., Cole S.M., et al. Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival. Blood 102 (2003) 344-352
95. Lee Y., Bone N., Strege A., et al. Epigallocatechin-3-gallate (EGCG) disrupts VEGF receptor-HIF (Hypoxia Inducible Factor 1-alpha) association. Implications for down-regulation of VEGF production and the induction of cell death in chronic lymphocytic luekmia (CLL) B-cells (2004) Proc Am Assoc Cancer Res Orlando, FL, March
96. Gerber H.P., Dixit V., and Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 273 (1998) 13313-13316
97. Nor J.E., Christensen J., Mooney D.J., et al. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 154 (1999) 375-384
98. Konig A., Menzel T., Lynen S., et al. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 11 (1997) 258-265
99. Bairey O., Zimra Y., Shaklai M., et al. Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia. Br J Haematol 113 (2001) 400-406
100. Mateo V., Lagneaux L., Bron D., et al. CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia. Nat Med 5 (1999) 1277-1284
101. Rutella S., Rumi C., Puggioni P., et al. Expression of thrombospondin receptor (CD36) in B-cell chronic lymphocytic leukemia as an indicator of tumor cell dissemination. Haematologica 84 (1999) 419-424
102. Panayiotidis P., Jones D., Ganeshaguru K., et al. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 92 (1996) 97-103
103. Lagneaux L., Delforge A., Bron D., et al. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 91 (1998) 2387-2396
104. Burger J.A., Tsukada N., Burger M., et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 96 (2000) 2655-2663
105. Fluckiger A.C., Rossi J.F., Bussel A., et al. Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors. Blood 80 (1992) 3173-3181
106. Buske C., Gogowski G., Schreiber K., et al. Stimulation of B-chronic lymphocytic leukemia cells by murine fibroblasts, IL-4, anti-CD40 antibodies, and the soluble CD40 ligand. Exp Hematol 25 (1997) 329-337
107. Kitada S., Zapata J.M., Andreeff M., et al. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 106 (1999) 995-1004
108. Granziero L., Ghia P., Circosta P., et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 97 (2001) 2777-2783
109. Furman R.R., Asgary Z., Mascarenhas J.O., et al. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 164 (2000) 2200-2206
110. Karin M., and Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 3 (2002) 221-227
111. Long B.W., Witte P.L., Abraham G.N., et al. Apoptosis and interleukin 7 gene expression in chronic B-lymphocytic leukemia cells. Proc Natl Acad Sci U S A 92 (1995) 1416-1420
112. Kay N., Strege A., Shanafelt T., et al. CLL B-cell interaction with bone biopsy generated marrow stromal elements enhances their apoptosis resistance in association with an angiogenic switch. Blood 104 (2004) 1914a (abstr)
113. Farahani M., Treweeke A.T., Toh C.H., et al. Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells. Leukemia 19 (2005) 524-530
114. Melter M., Reinders M.E., Sho M., et al. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood 96 (2000) 3801-3808
115. Cho C.S., Cho M.L., Min S.Y., et al. CD40 engagement on synovial fibroblast up-regulates production of vascular endothelial growth factor. J Immunol 164 (2000) 5055-5061
116. Tai Y.T., Podar K., Gupta D., et al. CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells. Blood 99 (2002) 1419-1427
117. Reinders M.E., Sho M., Robertson S.W., et al. Proangiogenic function of CD40 ligand-CD40 interactions. J Immunol (2003) 1711534-1711541
118. Till K.J., Spiller D.G., Harris R.J., et al. CLL, but not normal, B cells are dependent on autocrine VEGF and alpha4beta1 integrin for chemokine-induced motility on and through endothelium. Blood 105 (2005) 4813-4819
119. Shanafelt T.D., Geyer S.M., and Kay N.E. Prognosis at diagnosis. integrating molecular biologic insights into clinical practice for patients with CLL. Blood 103 (2004) 1202-1210
120. Gora-Tybor J., Blonski J.Z., and Robak T. Cladribine decreases the level of angiogenic factors in patients with chronic lymphocytic leukemia. Neoplasma 49 (2002) 145-148
121. D'Arena G., Valente V., Vigliotti M.L., et al. Improvement of B-cell chronic lymphocytic leukemia during haemodialysis. Possible role for endogenous production of factors involved in angiogenesis and apoptosis?. Leuk Lymphoma 44 (2003) 1263-1265
122. Shanafelt T., Geyer S., Bone N., et al. Evaluation of the prognostic implications of pro- and anti-angiogenic cytokines in 311 patients with untreated chronic lymphocytic leukemia. Blood 106 (2005) (abstr 712)
123. Molica S., Vitelli G., Levato D., et al. Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia. Eur J Haematol 70 (2003) 373-378
124. Tang Y., Nakada M.T., Kesavan P., et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 65 (2005) 3193-3199
125. Podar K., and Anderson K.C. The pathophysiologic role of VEGF in hematologic malignancies. Therapeutic implications. Blood 105 (2005) 1383-1395
126. Yang C.S. Inhibition of carcinogenesis by tea. Nature 389 (1997) 134-135
127. Cao Y., and Cao R. Angiogenesis inhibited by drinking tea. Nature 398 (1999) 381
128. Yang C.S., Chen L., Lee M.J., et al. Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol Biomarkers Prev 7 (1998) 351-354
129. Shanafelt TD, Lee YK, Call TG, et al: Clinical effects of oral green tea extracts in four patients with low grade b-cell malignancies. Leuk Res [e-pub Nov 2005]
130. Chow H.-H.S., Cai Y., Hakim I.A., et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenone in healthy individuals. Clin Cancer Res 9 (2003) 3312-3319
131. D'Amato R.J., Loughnan M.S., Flynn E., et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91 (1994) 4082-4085
132. Bartlett J.B., Dredge K., and Dalgleish A.G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4 (2004) 314-322
133. Rajkumar S.V., Hayman S., Gertz M.A., et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20 (2002) 4319-4323
134. Kay N., Geyer S., Yaqoob I., et al. Thalidomide treatment in B-chronic lymphocytic leukemia (CLL). A North Central Cancer Treatment Group study. Blood 102 (2003) (abstr 5162)
135. Furman R.R., Leonard J.P., Allen S.L., et al. Thalidomide alone or in combination with fludarabine are effective treatmetn for patients with fludarabine-relapsed and refractory CLL. Proc Am Soc Clin Oncol (2005) (abstr 6640)
136. Chanan-Khan A., Miller K.C., Takeshita K., et al. Thalidomide in combination with fludarabine as initial therapy for patients (pts) with treatment requiring chronic lymphocytic leukemia (CLL). Results of a phase I clinical trial. Blood 106 (2005) 3348-3352
137. Richardson P.G., Schlossman R.L., Weller E., et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100 (2002) 3063-3067
138. List A., Kurtin S., Roe D.J., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352 (2005) 549-557
139. Dredge K., Horsfall R., Robinson S.P., et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69 (2005) 56-63
140. Miller K.C., Czuczman M.S., Dimiceli L., et al. Anti-leukemic effects of novel immunimodulatory agent lenalidomide with or without rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Encouraging preliminary results of an ongoing phase II clinical study. Proc Am Soc Clin Oncol (2005) (abstr 6557)